In the case of insulin, I think it has more to do with the FDA's processes than corruption.
It would be very difficult to make a profit on generic insulin because it's a biologic drug, which means a generic manufacturer wouldn't be able to bypass the FDA approval process by proving bioequivalency.
EDIT: Upon further reading, there is a pathway[0][1] for "biosimilars", but it seems to have higher requirements than chemical generics.
It would be very difficult to make a profit on generic insulin because it's a biologic drug, which means a generic manufacturer wouldn't be able to bypass the FDA approval process by proving bioequivalency.
EDIT: Upon further reading, there is a pathway[0][1] for "biosimilars", but it seems to have higher requirements than chemical generics.
[0]: https://en.wikipedia.org/wiki/Biologics_Price_Competition_an...
[1]: https://www.fda.gov/drugs/biosimilars/biosimilar-and-interch...